August 2, 2010

AVEO Pharmaceuticals to Present at Cancer Stem Cells & The Tumor Microenvironment Conference

Download PDF

AVEO’s Patented Tivozanib Biomarker Highlighted as Part of IBC’s Drug Discovery & Development Week

CAMBRIDGE, Mass., Aug 02, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Murray Robinson, Ph.D., senior vice president, translational medicine, is scheduled to present at the Cancer Stem Cells & The Tumor Microenvironment Conference, part of IBC’s Drug Discovery & Development Week, on Monday, August 2, 2010 at 1:45 p.m. (PDT) at the Hyatt Regency San Francisco Airport in San Francisco.

Dr. Robinson will give a presentation, entitled “Myeloid Resistance Biomarkers for the VEGFR TKI Tivozanib Identified Using Next Generation Tumor Models,” that will focus on the utility of AVEO’s specific myeloid based multi-gene and IHC resistance biomarkers in assessing the activity of tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2 and 3, in human renal cell carcinoma (RCC).

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) blends a proprietary cancer biology platform with drug development and commercial expertise to discover and develop targeted cancer therapeutics. The company’s lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with a highly differentiated profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEO’s proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development and has provided a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the company’s website at

SOURCE: AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals, Inc.
Investor Contact:
Monique Allaire, 617-299-5810
Media Contact:
Pure Communications
Caton Lovett, 910-232-7166